News | January 20, 2026
Alto Neuroscience bags new US patent for depression drug ALTO-207
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Subscribe To Our Newsletter & Stay Updated
